Market Trends of Granisetron Industry
The Injection Segment is expected to witness significant growth in the market
Granisetron hydrochloride injection is a serotonin-3 (5-HT3) receptor antagonist indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The recommended dosage for granisetron hydrochloride injection in adults is 10 mcg/kg whereas the recommended dose in pediatric patients 2 to 16 years of age is 10 mcg/kg. When granisetron is used to prevent nausea and vomiting caused by cancer medicines (chemotherapy), it is usually given 30 minutes before the start of chemotherapy. However, when used to prevent and treat nausea and vomiting caused by surgery, it is usually given 30 seconds before anesthesia or right after surgery if nausea and vomiting begin.
As per the NCBI study published in September 2021, suggested that the use of subcutaneous granisetron reduced the total per-patient costs of care associated with unscheduled hydration compared with palonosetron in patients receiving emetogenic chemotherapy for breakthrough chemotherapy-induced nausea and vomiting events. Thus, the studies indicating the cost effectiveness of using granisetron over other alternatives will increase its demand, which will drive the segmental growth. Furthrmore, according to the NCBI study published in April 2021, granisetron injection decreased the sensitivity to mechanical stimuli and increased the sensitivity to heat indicating that granisetron injection can be considered a novel candidate for local anesthetics. Thus, the expanded use of granisetron injection will also lead top lucrative growth of the market.
Thus, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is the most affected region across the world, with a high prevalence of cancer. The United States is expected to hold a notable share in the North American region in the terms of cancer burden. With the rising prevalence of cancer and gastroparesis in the country, the studied market is expected to witness significant growth in the region.
According to the American Cancer Society, in 2022, there were an estimated 1,918,030 new cases of cancer in the United States, and 609,360 deaths were notified in the year 2022. In addition, according to the Public Health Agency of Canada data published in October 2021, approximately 2 in 5 Canadians were diagnosed with Cancer in their lifetime, and in 2021, an estimated 229,000 Canadians were diagnosed with Cancer. The report also mentioned that lung, breast, colorectal, and prostate cancers were expected to remain the most commonly diagnosed cancers, accounting for nearly 46% of all cancer diagnoses in 2021. The high incidence of cancer indicates the increasing patient visits for chemotherapy and radiotherapy, thereby increasing the demand for granisetron for addressing the symptoms thereby leading to positive growth of the market.
Furthermore, according to an NCBI study published in January 2021, the late phase of cycle 1 showed that transdermal granisetron was 82% more likely to control chemotherapy-induced nausea and vomiting than oral ondansetron, therefore preventive antiemetic medication for gynecologic cancer survivors undergoing chemoradiation should be taken into consideration. The studies, highlighting the clinical efficacies and safety of granisetron, which is expected to fuel market growth in the future.
Thus, the aforementioned factors are anticipated to lead to significant growth of the market in the region during the study period.
